Reynders McVeigh Capital Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $233K | Sell |
3,710
-530
| -13% | -$36.9K | 0.01% | 181 |
|
|
2025
Q4 | $281K | Hold |
4,240
| – | – | 0.01% | 169 |
|
|
2025
Q3 | $285K | Buy |
4,240
+60
| +1% | +$4.75K | 0.01% | 171 |
|
|
2025
Q2 | $365K | Hold |
4,180
| – | – | 0.02% | 154 |
|
|
2025
Q1 | $285K | Sell |
4,180
-1,272
| -23% | -$104K | 0.02% | 171 |
|
|
2024
Q4 | $424K | Sell |
5,452
-161
| -3% | -$11.9K | 0.02% | 146 |
|
|
2024
Q3 | $376K | Sell |
5,613
-2,502
| -31% | -$205K | 0.02% | 155 |
|
|
2024
Q2 | $920K | Sell |
8,115
-380
| -4% | -$48K | 0.05% | 98 |
|
|
2024
Q1 | $1.18M | Sell |
8,495
-3,100
| -27% | -$390K | 0.07% | 88 |
|
|
2023
Q4 | $1.44M | Sell |
11,595
-7,598
| -40% | -$776K | 0.09% | 81 |
|
|
2023
Q3 | $1.79M | Sell |
19,193
-3,075
| -14% | -$347K | 0.12% | 74 |
|
|
2023
Q2 | $2.86M | Sell |
22,268
-1,037
| -4% | -$125K | 0.19% | 65 |
|
|
2023
Q1 | $2.71M | Sell |
23,305
-1,248
| -5% | -$140K | 0.19% | 60 |
|
|
2022
Q4 | $2.78M | Sell |
24,553
-635
| -3% | -$69.7K | 0.2% | 62 |
|
|
2022
Q3 | $2.03M | Sell |
25,188
-1,200
| -5% | -$102K | 0.16% | 65 |
|
|
2022
Q2 | $1.97M | Sell |
26,388
-80
| -0.3% | -$7.3K | 0.15% | 67 |
|
|
2022
Q1 | $3.38M | Sell |
26,468
-1,260
| -5% | -$138K | 0.21% | 59 |
|
|
2021
Q4 | $3.72M | Sell |
27,728
-2,420
| -8% | -$348K | 0.21% | 60 |
|
|
2021
Q3 | $4.12M | Sell |
30,148
-40
| -0.1% | -$5.04K | 0.25% | 55 |
|
|
2021
Q2 | $3.22M | Sell |
30,188
-104
| -0.3% | -$9.99K | 0.2% | 64 |
|
|
2021
Q1 | $2.72M | Sell |
30,292
-1,956
| -6% | -$184K | 0.18% | 67 |
|
|
2020
Q4 | $2.98M | Sell |
32,248
-2,824
| -8% | -$252K | 0.2% | 62 |
|
|
2020
Q3 | $3.61M | Buy |
35,072
+728
| +2% | +$76.1K | 0.28% | 56 |
|
|
2020
Q2 | $3.48M | Sell |
34,344
-5,132
| -13% | -$459K | 0.3% | 54 |
|
|
2020
Q1 | $2.66M | Sell |
39,476
-2,492
| -6% | -$155K | 0.3% | 56 |
|
|
2019
Q4 | $2.29M | Sell |
41,968
-732
| -2% | -$34.7K | 0.22% | 64 |
|
|
2019
Q3 | $1.59M | Buy |
42,700
+460
| +1% | +$17.9K | 0.17% | 78 |
|
|
2019
Q2 | $1.58M | Sell |
42,240
-1,440
| -3% | -$45.3K | 0.17% | 79 |
|
|
2019
Q1 | $1.3M | Hold |
43,680
| – | – | 0.14% | 90 |
|
|
2018
Q4 | $1.31M | Hold |
43,680
| – | – | 0.17% | 80 |
|
|
2018
Q3 | $1.56M | Hold |
43,680
| – | – | 0.18% | 83 |
|
|
2018
Q2 | $1.04M | Sell |
43,680
-280
| -0.6% | -$5.94K | 0.13% | 97 |
|
|
2018
Q1 | $815K | Sell |
43,960
-500
| -1% | -$7.39K | 0.1% | 106 |
|
|
2017
Q4 | $638K | Buy |
+44,460
| New | +$578K | 0.08% | 121 |
|
Other funds holding DXCM
VCM
VPM
Reynders McVeigh Capital Management's DXCM Position: Q1 2026 in Review
Reynders McVeigh Capital Management reduced its DexCom (DXCM) stake by 13% in Q1 2026, selling an estimated $36.9K and leaving 3,710 shares worth $233K. The position accounts for 0.01% of the portfolio, ranked #181.
Reynders McVeigh Capital Management first reported a position in DXCM in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.12M in Q3 2021. 959 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Reynders McVeigh Capital Management held 3,710 shares of DexCom worth $233K as of Q1 2026.
- Reynders McVeigh Capital Management sold 530 DexCom shares in Q1 2026, an estimated $36.9K.
- DexCom made up 0.01% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #181 holding.
- Reynders McVeigh Capital Management first reported a position in DexCom in Q4 2017 and has held it in 34 quarters since.
- Reynders McVeigh Capital Management's DexCom position peaked at $4.12M in Q3 2021.
- 959 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.